RU2001124810A - SELECTION OF PROTEINS USING RNA-PROTEIN HYBRID - Google Patents

SELECTION OF PROTEINS USING RNA-PROTEIN HYBRID

Info

Publication number
RU2001124810A
RU2001124810A RU2001124810/13A RU2001124810A RU2001124810A RU 2001124810 A RU2001124810 A RU 2001124810A RU 2001124810/13 A RU2001124810/13 A RU 2001124810/13A RU 2001124810 A RU2001124810 A RU 2001124810A RU 2001124810 A RU2001124810 A RU 2001124810A
Authority
RU
Russia
Prior art keywords
protein
sequence
rna
specified
dna sequence
Prior art date
Application number
RU2001124810/13A
Other languages
Russian (ru)
Other versions
RU2238326C2 (en
Inventor
Джек В. ЖОСТАК
Ричард В. РОБЕРТС
Райх ЛИУ
Original Assignee
Дзе Дженерал Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/247,190 external-priority patent/US6261804B1/en
Application filed by Дзе Дженерал Хоспитал Корпорейшн filed Critical Дзе Дженерал Хоспитал Корпорейшн
Publication of RU2001124810A publication Critical patent/RU2001124810A/en
Application granted granted Critical
Publication of RU2238326C2 publication Critical patent/RU2238326C2/en

Links

Claims (23)

1. Способ продуцирования библиотеки белков, включающий стадии:1. A method of producing a protein library, comprising the steps of: a) получения популяции РНК-молекул, каждая из которых включает последовательность инициации трансляции и старт-кодон, функционально присоединенный к кодирующей белок последовательности, и каждая из которых функционально присоединена к пептидному акцептору у 3’-конца указанной кодирующей белок последовательности;a) obtaining a population of RNA molecules, each of which includes a translation initiation sequence and a start codon, operably linked to a protein coding sequence, and each of which is operably linked to a peptide acceptor at the 3 ′ end of said protein coding sequence; b) in vitro трансляции указанных кодирующих белок последовательностей с продуцированием популяции гибридов "РНК-белок"; иb) in vitro translation of the indicated protein-coding sequences with the production of a population of RNA-protein hybrids; and c) последующего инкубирования указанной популяции гибридов "РНК-белок" в условиях содержания высшей соли с получением библиотеки белков.c) subsequent incubation of the indicated population of RNA-protein hybrids under conditions of higher salt content to obtain a protein library. 2. Способ продуцирования библиотеки ДНК, включающий стадии:2. A method of producing a DNA library, comprising the steps of: a) получения популяции РНК-молекул, каждая из которых включает последовательность инициации трансляции и старт-кодон, функционально присоединенный к кодирующей белок последовательности, и каждая из которых функционально присоединена к пептидному акцептору у 3’-конца указанной кодирующей белок последовательности;a) obtaining a population of RNA molecules, each of which includes a translation initiation sequence and a start codon, operably linked to a protein coding sequence, and each of which is operably linked to a peptide acceptor at the 3 ′ end of said protein coding sequence; b) in vitro трансляции указанных кодирующих белок последовательностей с продуцированием популяции гибридов "РНК-белок"; иb) in vitro translation of the indicated protein-coding sequences with the production of a population of RNA-protein hybrids; and c) последующего инкубирования указанной популяции гибридов "РНК-белок" в условиях содержания высшей соли; иc) subsequent incubation of the indicated population of RNA-protein hybrids under conditions of higher salt; and d) генерирования ДНК-молекулы из каждого из указанных РНК-частей указанных гибридов с получением библиотеки ДНК.d) generating a DNA molecule from each of said RNA portions of said hybrids to produce a DNA library. 3. Способ отбора нужного белка или нуклеиновой кислоты, кодирующей указанный белок, включающий стадии:3. A method of selecting the desired protein or nucleic acid encoding a specified protein, comprising the steps of: a) получения популяции РНК-молекул-кандидатов, каждая из которых включает последовательность инициации трансляции и старт-кодон, функционально присоединенный к последовательности, кодирующей белок-кандидат, и каждая из которых функционально присоединена к пептидному акцептору у 3’-конца указанной последовательности, кодирующей белок-кандидат;a) obtaining a population of candidate RNA molecules, each of which includes a translation initiation sequence and a start codon, functionally attached to a sequence encoding a candidate protein, and each of which is functionally attached to a peptide acceptor at the 3'-end of the specified sequence encoding candidate protein; b) in vitro трансляции указанных последовательностей, кодирующих белок-кандидат, с продуцированием популяции гибридов кандидатов РНК-белок;b) in vitro translation of the indicated sequences encoding a candidate protein, with the production of a population of candidate RNA protein hybrids; c) последующего инкубирования указанной популяции гибридов-кандидатов "РНК-белок" в условиях содержания высшей соли с получением библиотеки белков; иc) subsequent incubation of the indicated population of candidate RNA-protein hybrids under conditions of higher salt content to obtain a protein library; and d) отбора нужного гибрида РНК-белок, и, тем самым, отбора указанного нужного белка и нуклеиновой кислоты, кодирующей указанный белок.d) selecting the desired fusion of RNA protein, and thereby selecting said desired protein and nucleic acid encoding said protein. 4. Способ по любому из пп.1-3, отличающийся тем, что указанная высшая соль включает одновалентный катион.4. The method according to any one of claims 1 to 3, characterized in that said higher salt comprises a monovalent cation. 5. Способ по любому из пп.1-3, отличающийся тем, что указанный одновалентный катион присутствует в концентрации приблизительно 125 мМ - 1,5 М.5. The method according to any one of claims 1 to 3, characterized in that the monovalent cation is present in a concentration of approximately 125 mm - 1.5 M. 6. Способ по п.5, отличающийся тем, что указанный одновалентный катион присутствует в концентрации приблизительно 300 мМ - 600 мМ.6. The method according to claim 5, characterized in that the monovalent cation is present in a concentration of approximately 300 mm to 600 mm. 7. Способ по п.4, отличающийся тем, что указанным одновалентным катионом является К+ или NH4 +.7. The method according to claim 4, characterized in that said monovalent cation is K + or NH 4 + . 8. Способ по п.7, отличающийся тем, что указанным одновалентным катионом является Na+ 8. The method according to claim 7, characterized in that said monovalent cation is Na + 9. Способ по п.1, отличающийся тем, что указанную стадию инкубирования осуществляют приблизительно при комнатной температуре.9. The method according to claim 1, characterized in that the specified stage of incubation is carried out at approximately room temperature. 10. Способ по любому из пп.1-3, отличающийся тем, что указанная высшая соль содержит двухвалентный катион.10. The method according to any one of claims 1 to 3, characterized in that said higher salt contains a divalent cation. 11. Способ по п.10, отличающийся тем, что указанный двухвалентный катион присутствует в концентрации приблизительно 25 мМ - 200 мМ.11. The method according to claim 10, characterized in that the divalent cation is present in a concentration of approximately 25 mm to 200 mm. 12. Способ по п.10, отличающийся тем, что указанным двухвалентным катионом является Mg+2.12. The method according to claim 10, characterized in that said divalent cation is Mg +2 . 13. Способ по любому из пп.1-3, отличающийся тем, что указанная высшая соль включает как одновалентный катион, так и двухвалентный катион.13. The method according to any one of claims 1 to 3, characterized in that said higher salt comprises both a monovalent cation and a divalent cation. 14. Способ по любому из пп.1-3, отличающийся тем, что каждая из указанных РНК-молекул кроме того включает стоп-последовательность, или кроме того включает ДНК-последовательность или аналог ДНК-последовательности, ковалентно связанный с 3’-концом указанной РНК-молекулы.14. The method according to any one of claims 1 to 3, characterized in that each of these RNA molecules further comprises a stop sequence, or in addition includes a DNA sequence or an analog of a DNA sequence covalently linked to the 3'-end of said RNA molecules. 15. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности имеет длину, достаточную для того, чтобы присутствовал интервал между декодирующим сайтом и пептидилтрансферазным центром рибосомы.15. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analogue of the DNA sequence has a length sufficient so that there is an interval between the decoding site and the peptidyl transferase center of the ribosome. 16. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности имеет длину приблизительно 60-70 А.16. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analogue of the DNA sequence has a length of approximately 60-70 A. 17. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности имеет длину приблизительно менее, чем 80 нуклеотидов.17. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analogue of the DNA sequence has a length of approximately less than 80 nucleotides. 18. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности имеет длину приблизительно менее, чем 45 нуклеотидов.18. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analogue of the DNA sequence has a length of approximately less than 45 nucleotides. 19. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности имеет длину приблизительно 21-30 нуклеотидов.19. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analogue of the DNA sequence has a length of approximately 21-30 nucleotides. 20. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности присоединен к указанной РНК-молекуле с использованием "ДНК-шунта".20. The method of claim 14, wherein said stop sequence or said DNA sequence or an analog of a DNA sequence is attached to said RNA molecule using a “DNA shunt”. 21. Способ по п.14, отличающийся тем, что указанная стоп-последовательность или указанная ДНК-последовательность или аналог ДНК-последовательности содержит ненуклеотидную часть.21. The method according to 14, characterized in that the specified stop sequence or the specified DNA sequence or analog of the DNA sequence contains a non-nucleotide part. 22. Способ по п.14, отличающийся тем, что указанной ненуклеотидной частью является одна или несколько составляющих НО (СН2СН2О)3РО2) (фосфат полиэтиленгликоля).22. The method according to 14, characterized in that said non-nucleotide part is one or more constituents of HO (CH 2 CH 2 O) 3 PO 2 ) (polyethylene glycol phosphate). 23. Способ по любому из пп.1-3, отличающийся тем, что указанный гибрид "РНК-белок", кроме того, включает нуклеиновую кислоту или аналог нуклеиновой кислоты, расположенные возле указанного пептидного акцептора, который увеличивает гибкость.23. The method according to any one of claims 1 to 3, characterized in that said RNA-protein hybrid further comprises a nucleic acid or nucleic acid analog located near said peptide acceptor, which increases flexibility.
RU2001124810A 1999-02-09 2000-02-01 Method for producing library of genes (variants), method for selection of necessary protein and nucleic acid RU2238326C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/247,190 US6261804B1 (en) 1997-01-21 1999-02-09 Selection of proteins using RNA-protein fusions
US09/247,190 1999-02-09

Publications (2)

Publication Number Publication Date
RU2001124810A true RU2001124810A (en) 2003-07-20
RU2238326C2 RU2238326C2 (en) 2004-10-20

Family

ID=22933957

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001124810A RU2238326C2 (en) 1999-02-09 2000-02-01 Method for producing library of genes (variants), method for selection of necessary protein and nucleic acid

Country Status (18)

Country Link
US (3) US6261804B1 (en)
EP (1) EP1151143B1 (en)
JP (1) JP4870870B2 (en)
KR (1) KR100713953B1 (en)
AT (1) ATE428000T1 (en)
AU (1) AU773236B2 (en)
CA (1) CA2361725C (en)
CY (1) CY1109198T1 (en)
DE (1) DE60041958D1 (en)
DK (1) DK1151143T3 (en)
ES (1) ES2324512T3 (en)
HK (1) HK1042524B (en)
IL (2) IL144518A0 (en)
NO (1) NO329348B1 (en)
NZ (1) NZ513153A (en)
PT (1) PT1151143E (en)
RU (1) RU2238326C2 (en)
WO (1) WO2000047775A1 (en)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016636A1 (en) * 1996-10-17 1998-04-23 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
CA2323638A1 (en) * 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
AU775997B2 (en) * 1998-12-02 2004-08-19 Bristol-Myers Squibb Company DNA-protein fusions and uses thereof
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000072869A1 (en) 1999-06-01 2000-12-07 Phylos, Inc. Methods for producing 5'-nucleic acid-protein conjugates
DK1196637T3 (en) * 1999-07-27 2007-07-30 Adnexus Therapeutics Inc Peptide ligation methods
US6436665B1 (en) 1999-08-27 2002-08-20 Phylos, Inc Methods for encoding and sorting in vitro translated proteins
ATE322558T1 (en) * 2000-01-24 2006-04-15 Compound Therapeutics Inc SENSITIVE AND MULTIPLEX DIAGNOSTIC TESTS FOR PROTEIN ANALYSIS
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US20010024789A1 (en) * 2000-02-24 2001-09-27 Markus Kurz Methods for generating catalytic proteins
US7410761B2 (en) * 2000-05-19 2008-08-12 Proteonova, Inc. System for rapid identification and selection of nucleic acids and polypeptides, and method thereof
US6962781B1 (en) * 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US20040229271A1 (en) 2000-05-19 2004-11-18 Williams Richard B. Compositions and methods for the identification and selection of nucleic acids and polypeptides
JP4963142B2 (en) * 2000-12-14 2012-06-27 学校法人慶應義塾 Genotype-phenotype mapping molecule and its constituents, and method for producing and using mapping molecule
EP1353941B1 (en) 2001-01-22 2013-03-13 Sangamo BioSciences, Inc. Modified zinc finger binding proteins
US7070928B2 (en) 2001-03-19 2006-07-04 President And Fellows Of Harvard College Evolving new molecular function
WO2002102820A1 (en) 2001-06-20 2002-12-27 Nuevolution A/S Nucleoside derivatives for library preparation
EP1402024B1 (en) 2001-06-20 2007-08-22 Nuevolution A/S Templated molecules and methods for using such molecules
JP2004537312A (en) * 2001-07-31 2004-12-16 フィロス インク． Modular assembly of nucleic acid-protein fusion multimers
DE10145226A1 (en) * 2001-09-13 2003-04-10 Lifebits Ag Manufacture of carrier-bound molecules
AU2002356984A1 (en) * 2001-11-16 2003-06-10 Proteonova, Inc. Selection and evolution of nucleic acids and polypeptides
AU2002365404A1 (en) * 2001-11-27 2003-06-10 Compound Therapeutics, Inc. Solid-phase immobilization of proteins and peptides
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
IL163822A0 (en) 2002-03-15 2005-12-18 Nuevolution As An improved method for synthesising templated molecules
US20030235852A1 (en) * 2002-04-19 2003-12-25 Roberts Richard W. Nucleic acid-peptide display libraries containing peptides with unnatural amino acid residues, and methods of making same using peptide modifying agents
US20030198973A1 (en) * 2002-04-23 2003-10-23 The Molecular Sciences Institute, Inc. Chimeric fusion molecule for analyte detection and quantitation
US20060073481A1 (en) * 2002-04-23 2006-04-06 The Molecular Sciences Institute Formation and use of site specific nucleic acid coupled binding polypeptides
AU2003240436A1 (en) * 2002-06-20 2004-01-06 Nuevolution A/S Microarrays displaying encoded molecules
WO2004013070A2 (en) 2002-08-01 2004-02-12 Nuevolution A/S Multi-step synthesis of templated molecules
AU2003263937B2 (en) 2002-08-19 2010-04-01 The President And Fellows Of Harvard College Evolving new molecular function
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
PT1558744E (en) 2002-10-30 2011-09-22 Nuevolution As Enzymatic encoding
ATE450609T1 (en) 2002-12-19 2009-12-15 Nuevolution As SYNTHESIS METHOD GUIDED BY QUASI-RANDOM STRUCTURES AND FUNCTIONS
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
EP1597395A2 (en) 2003-02-21 2005-11-23 Nuevolution A/S Method for producing second-generation library
ATE424455T1 (en) 2003-03-20 2009-03-15 Nuevolution As LIGATION-MEDIATING CODING OF SMALL MOLECULES
EP1670939B1 (en) 2003-09-18 2009-11-04 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
AU2004296376B2 (en) * 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20050191662A1 (en) * 2003-12-22 2005-09-01 Syngenta Participations Ag In vitro screening and evolution of proteins
ATE447020T1 (en) 2004-03-22 2009-11-15 Nuevolution As LIGATION CODING USING OLIGONUCLEOTIDE BUILDING BLOCKS
DE602006014362D1 (en) * 2005-02-02 2010-07-01 Univ Bayreuth ESTERASES FOR MONITORING THE PROTEIN BIOSYNTHESIS IN VITRO
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
EP1785434A1 (en) 2005-11-11 2007-05-16 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
DE602006018648D1 (en) 2005-12-01 2011-01-13 Nuevolution As ENZYMMETRING CODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES
US7749957B2 (en) 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
EP2405272B1 (en) 2006-06-30 2015-01-14 DiscoveRx Corporation Detectable nucleic acid tag
BRPI0719597A2 (en) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company OBJECTIVE THERAPEUTIC PRODUCTS BASED ON HANDLED PROTEINS FOR TYROSINE KINASE RECEPTORS, INCLUDING IGF-IR
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
US7951559B2 (en) * 2007-07-25 2011-05-31 E.I. Du Pont De Nemours And Company Recombinant peptide production using a cross-linkable solubility tag
US7829311B2 (en) 2007-07-25 2010-11-09 E.I. Du Pont De Nemours And Company Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
BRPI0816785A2 (en) 2007-09-14 2017-05-02 Adimab Inc rationally designed synthetic antibody libraries, and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2209491B1 (en) 2007-11-02 2015-10-28 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
US7794963B2 (en) 2007-11-02 2010-09-14 E.I. Du Pont De Nemours And Company Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
NZ709704A (en) 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (en) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Scaffold domain protein based on multivalent fibronectin
JP5924937B2 (en) 2008-07-25 2016-05-25 エックス−ボディ インコーポレイテッド Protein screening method
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
US20100158822A1 (en) * 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158837A1 (en) 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Iron oxide-binding peptides
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
US20100247590A1 (en) * 2009-03-30 2010-09-30 Johnson & Johnson Peptide-Based Systems For Delivery Of Cosmetic Agents
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20120208720A1 (en) * 2009-10-22 2012-08-16 Kenji Kashiwagi Rapid display method in translational synthesis of peptide
ES2860453T3 (en) 2009-10-30 2021-10-05 Novartis Ag Universal libraries of type III fibronectin underside binding domain
WO2011054893A2 (en) 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
KR20120125357A (en) 2010-02-10 2012-11-14 노파르티스 아게 Methods and compounds for muscle growth
BR112012019881A2 (en) 2010-02-18 2017-06-27 Bristol Myers Squibb Co fibronectin-based structural domain proteins that bind to il-23
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
PT2556171E (en) 2010-04-05 2015-12-21 Prognosys Biosciences Inc Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
ES2713873T3 (en) 2010-04-16 2019-05-24 Nuevolution As Bifunctional complexes and methods for making and using such complexes
EP3569256B1 (en) * 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
PT2591125T (en) * 2010-07-09 2018-05-09 Cergentis B V V3-d genomic region of interest sequencing strategies
MX360336B (en) 2010-07-16 2018-10-30 Adimab Llc Star Antibody libraries.
EP3248987A1 (en) 2010-07-30 2017-11-29 Novartis AG Fibronectin cradle molecules and libraries thereof
AU2011323124C1 (en) 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
WO2012074130A1 (en) * 2010-12-03 2012-06-07 国立大学法人東京大学 Peptide library production method, peptide library, and screening method
US9260496B2 (en) 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
DE102010056289A1 (en) 2010-12-24 2012-06-28 Geneart Ag Process for the preparation of reading frame correct fragment libraries
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
EP2686349B1 (en) 2011-03-15 2020-12-09 X-Body, Inc. Antibody screening methods
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PT2697257T (en) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Fc fusion proteins comprising novel linkers or arrangements
PT2702146T (en) 2011-04-28 2019-04-22 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
CN103890582A (en) 2011-06-02 2014-06-25 麻省理工学院 DsRNA/DNA hybrid genome replication intermediate of metakaryotic stem cells
WO2013019794A1 (en) 2011-08-01 2013-02-07 The General Hospital Corporation Protein and peptide libraries
WO2013034579A1 (en) 2011-09-05 2013-03-14 Rheinische Friedrich-Wilhelms-Universität Bonn Biosynthetic gene cluster for the production of peptide/protein analogues
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CA2857721C (en) 2011-12-05 2022-05-31 X-Body, Inc. Pdgf receptor beta binding polypeptides
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
CN104768969B (en) 2012-09-13 2021-04-16 百时美施贵宝公司 Fibronectin based scaffold domain proteins that bind to myostatin
US20160068835A1 (en) * 2013-01-30 2016-03-10 Peptidream Inc. Flexible display method
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
JP6416793B2 (en) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド Tuberculosis biomarkers and uses thereof
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US10132816B2 (en) 2013-03-14 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Measurement of FGF21 as a biomarker of fructose metabolism
CN111233978A (en) 2013-03-15 2020-06-05 普罗格诺西斯生物科学公司 Methods for detecting peptide/MHC/TCR binding
WO2014145458A1 (en) * 2013-03-15 2014-09-18 Arizona Board Of Regents On Behalf Of Arizona State University Nucleic acid-tagged compositions and methods for multiplexed protein-protein interaction profiling
WO2014189843A1 (en) 2013-05-20 2014-11-27 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
ES2791068T3 (en) 2013-06-28 2020-10-30 X Body Inc Discovery of target antigens, phenotypic screens and use of them for the identification of specific target epitopes of target cells
CA2924879C (en) 2013-09-23 2023-01-10 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
GB201322692D0 (en) 2013-12-20 2014-02-05 Philochem Ag Production of encoded chemical libraries
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
MX2016011580A (en) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains.
EP4223317A3 (en) 2014-06-12 2023-09-27 RA Pharmaceuticals, Inc. Modulation of complement activity
CN106573961B (en) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 CHAGASIN-based scaffold compositions, methods and uses
CN107207379B (en) 2014-11-25 2021-08-10 百时美施贵宝公司 For biological products18Methods and compositions for F-radiolabelling
ES2822990T3 (en) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novel PD-L1 Binding Polypeptides for Imaging
SI3250230T1 (en) 2015-01-28 2022-01-31 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2016134521A1 (en) 2015-02-27 2016-09-01 The University Of Hong Kong Dna display and methods thereof
CN113186256A (en) 2015-04-10 2021-07-30 空间转录公司 Spatially differentiated, multiplexed nucleic acid analysis of biological samples
AU2016245887B2 (en) 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
ES2884267T3 (en) 2015-04-24 2021-12-10 Viiv Healthcare Uk No 5 Ltd Polypeptides Targeted for HIV Fusion
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
ES2809125T3 (en) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Glypican-3 binding fibronectin-based scaffold molecules
FI3685847T3 (en) 2015-12-16 2023-04-03 Ra Pharmaceuticals Inc Modulators of complement activity
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
JP2019520421A (en) * 2016-04-01 2019-07-18 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． Array-based peptide library for characterization of therapeutic antibodies
WO2017189409A1 (en) * 2016-04-25 2017-11-02 Evorx Technologies, Inc. Beta-catenin barcoded peptides
CN109562195A (en) 2016-06-01 2019-04-02 百时美施贵宝公司 PET imaging is carried out with PD-L1 combination polypeptide
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US11359112B2 (en) 2016-11-09 2022-06-14 Cowper Sciences Inc. Coatings with tunable amine density
BR112019011053A2 (en) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc complement activity modulators
SG11201908579PA (en) * 2017-03-17 2019-10-30 Cubicstars Inc Method for producing complex of rna molecule and peptide, and utilization thereof
WO2019123262A1 (en) 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN112236450A (en) * 2018-03-26 2021-01-15 根路径基因组学公司 Compositions of target binding moieties and methods of use
EP3894590A2 (en) 2018-12-10 2021-10-20 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
EP3806895B1 (en) * 2019-02-15 2023-06-21 Atreca, Inc. Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
CN110777158B (en) * 2019-03-13 2022-01-21 深圳市臻质医疗科技有限公司 DNA fragment, mRNA-antibody fusion molecule with cell specific binding capacity and preparation method thereof
KR20220005568A (en) 2019-05-09 2022-01-13 제넨테크, 인크. Methods for making antibodies
JP2023515633A (en) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー Radiolabeled fibronectin-based scaffolds and antibodies and their theranostic uses
CN112851771A (en) * 2021-02-09 2021-05-28 中国科学院武汉病毒研究所 Method for linking nucleic acids to proteins or peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
CH0229046H1 (en) 1985-03-30 1998-07-15 Stuart Alan Kauffman METHOD FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTINIQUE. DES OR PROTEINS BY MEANS OF A DNA RECOMBINANT TECH
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
WO1992002536A1 (en) 1990-08-02 1992-02-20 The Regents Of The University Of Colorado Systematic polypeptide evolution by reverse translation
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5795747A (en) 1991-04-16 1998-08-18 Evotec Biosystems Gmbh Process for manufacturing new biopolymers
DE4112440C1 (en) 1991-04-16 1992-10-22 Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De
AU2313392A (en) 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
PT1231268E (en) * 1994-01-31 2005-11-30 Univ Boston BANKS OF POLYCLONE ANTIBODIES
US5561043A (en) 1994-01-31 1996-10-01 Trustees Of Boston University Self-assembling multimeric nucleic acid constructs
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5627024A (en) * 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5559000A (en) 1995-01-18 1996-09-24 The Scripps Research Institute Encoded reaction cassette
DE19646372C1 (en) 1995-11-11 1997-06-19 Evotec Biosystems Gmbh Conjugates of polypeptide and encoding nucleic acid
US5789024A (en) 1996-05-15 1998-08-04 New Jersey Institute Of Technology Subnanoscale composite, N2-permselective membrane for the separation of volatile organic compounds
WO1998016636A1 (en) 1996-10-17 1998-04-23 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
ATE332368T1 (en) * 1997-01-21 2006-07-15 Gen Hospital Corp SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6440695B1 (en) 1998-04-17 2002-08-27 Whitehead Institute For Biomedical Research Method for producing diverse libraries of encoded polypeptides
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function

Similar Documents

Publication Publication Date Title
RU2001124810A (en) SELECTION OF PROTEINS USING RNA-PROTEIN HYBRID
CA2361725A1 (en) Selection of proteins using rna-protein fusions
Frankel et al. Encodamers: unnatural peptide oligomers encoded in RNA
US6423493B1 (en) Combinatorial selection of oligonucleotide aptamers
US6312927B1 (en) Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
CN107709555A (en) The unidirectional of synthesis for the gene editing of Cas9 mediations leads RNA
RU99118585A (en) SELECTION OF PROTEINS USING RNA-PEPTIDE HYBRIDS
Smiley et al. Sequences of the Escherichia coli dnaG primase gene and regulation of its expression.
JPH02142472A (en) Method for preparation of double-stranded dna sequence
CN1047402C (en) DNA sequences encoding gelonin polypeptide
PT917571E (en) GENE RELATED TO AGOUTI
DE69941269D1 (en) IMPROVED METHODS OF INCLUSION OF NUCLEIC ACIDS IN RINGED VECTORS
DE69926061D1 (en) METHOD AND COMPOSITIONS FOR THE PEPTIDE SYNTHESIS (T-20)
EA004509B1 (en) Dna encoding human bone morphogenetic protein -7 comprising promoter region encoding said protein and method for preparing thereof
JPH05214000A (en) Maturation polypeptide
AU6177101A (en) In vitro evolution of nucleic acids and encoded polypeptide
WO1993017031A3 (en) Nucleic acids encoding dystrophin-associated proteins
CA2456105A1 (en) Modular assembly of nucleic acid-protein fusion multimers
Azhikina et al. Strings of contiguous modified pentanucleotides with increased DNA-binding affinity can be used for DNA sequencing by primer walking.
JPS63304987A (en) Gene engineering production of angiogenins
DK175230B1 (en) Method for producing double-stranded DNA as well as oligonucleotide
JP6618534B2 (en) Amino acid modified nucleic acids and their use
AR025482A1 (en) DNA SEQUENCE CODING A PROTEIN ABLE TO BIND TRAF; VECTOR UNDERSTANDING SUCH SEQUENCE; GUEST CELLS TRANSFORMED WITH SUCH VECTOR; PROTEINS IREN CODED BY SUCH SEQUENCE; METHOD FOR PRODUCING THE PROTEIN; SPECIFIC ANTIBODIES FOR SUCH PROTEINS; METHOD FOR M
JPS58183659A (en) Modified proinsulin precursor, dna arrangement for coding same and production thereof
JPS61152695A (en) Synthesis of long-chain dna